Neuroimaging predictors of brain amyloidosis in mild cognitive impairment

Annals of Neurology

Volumn 74, Issue 2, 2013, Pages 188-198

  Tosun, Duygu ^a,b   Joshi, Sarang ^c   Weiner, Michael W ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CARBON 11; PITTSBURGH COMPOUND B;

AGED; ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; AMYLOIDOSIS; ARTICLE; BRAIN FORNIX; BRAIN SIZE; CAUDATE NUCLEUS; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENOTYPE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIAL TEMPORAL LOBE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRECUNEUS; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STRIA TERMINALIS; TEMPORAL CORTEX; TEMPORAL LOBE;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; AMYLOIDOSIS; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; BRAIN CHEMISTRY; FEMALE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS;

EID: 84884902857     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23921     Document Type: Article

References (46)

1. Braak H, Braak E,. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259.
2. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403-413.
3. Jagust WJ, Bandy D, Chen K, et al. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimer Dement 2010; 6: 221-229.
4. Lister-James J, Pontecorvo MJ, Clark C, et al. Florbetapir F-18: a histopathologically validated beta-amyloid positron emission tomography imaging agent. Semin Nucl Med 2011; 41: 300-304.
5. Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol 2012; 11: 669-678.
6. Driscoll I, Troncoso JC, Rudow G, et al. Correspondence between in vivo 11C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. Acta Neuropathol 2012; 124: 823-831.
7. Clark CM, Xie S, Chittams J, et al. Cerebrospinal fluid tau and β-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 2003; 60: 1696-1702.
8. Rabinovici GD, Jagust WJ,. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol 2009; 21: 117-128.
9. Nordberg A,. Amyloid imaging in Alzheimer's disease. Curr Opin Neurol 2007; 20: 398-402.
10. Apostolova L, Hwang K, Kohannim O,. Predicting brain amyloidosis in MCI using clinical, cognitive, imaging and peripheral blood protein measures. Paper presented at: Alzheimer's Association International Conference; July 14-19, 2012; Vancouver, British Columbia, Canada.
11. Mielke MM, Wiste HJ, Weigand SD, et al. Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology 2012; 79: 1570-1577.
12. Bahar-Fuchs A, Villemagne V, Ong K, et al. Prediction of amyloid-beta pathology in amnestic mild cognitive impairment with neuropsychological tests. J Alzheimers Dis 2013; 33: 451-462.
13. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer Dement 2011; 7: 263-269.
14. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008; 131: 665-680.
15. Chetelat G, Villemagne VL, Bourgeat P, et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 2010; 67: 317-324.
16. Bourgeat P, Chetelat G, Villemagne VL, et al. β-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 2010; 74: 121-127.
17. Archer HA, Edison P, Brooks DJ, et al. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol 2006; 60: 145-147.
18. Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated β-amyloid deposition in elderly subjects. Brain 2009; 132: 1310-1323.
19. Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 2009; 73: 287-293.
20. Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 2009; 73: 294-301.
21. Apostolova LG, Dutton RA, Dinov ID, et al. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch Neurol 2006; 63: 693-699.
22. Vemuri P, Wiste HJ, Weigand SD, et al. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol 2010; 67: 308-316.
23. Pievani M, Rasser PE, Galluzzi S, et al. Mapping the effect of APOE ε4 on gray matter loss in Alzheimer's disease in vivo. Neuroimage 2009; 45: 1090-1098.
24. Schuff N, Woerner N, Boreta L, et al. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain 2009; 132: 1067-1077.
25. Weiner MW, Veitch DP, Aisen PS, et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimer Dement 2012; 8 (1 suppl): S1-S68.
26. Becker JA, Hedden T, Carmasin J, et al. Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol 2011; 69: 1032-1042.
27. Jack CR, Bernstein MA, Fox NC, et al. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging 2008; 27: 685-691.
28. Shattuck DW, Leahy RM,. BrainSuite: an automated cortical surface identification tool. Med Image Anal 2002; 6: 129-142.
29. Jiang T, Navab N, Pluim J, et al, eds. Multivariate statistical analysis of deformation momenta relating anatomical shape to neuropsychological measures. Medical Image Computing and Computer-Assisted Intervention-MICCAI 2010. Berlin/Heidelberg, Germany: Springer, 2010.
30. Wold S, Geladi P, Esbensen K, Öhman J,. Multi-way principal components and PLS analysis. J Chemometrics 1987; 1: 41-56.
31. Jagust WJ, Landau SM, Shaw LM, et al. Relationships between biomarkers in aging and dementia. Neurology 2009; 73: 1193-1199.
32. Scheinin NM, Tolvanen TK, Wilson IA, et al. Biodistribution and radiation dosimetry of the amyloid imaging agent 11C-PIB in humans. J Nucl Med 2007; 48: 128-133.
33. O'Keefe GJ, Saunder TH, Ng S, et al. Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172. J Nucl Med 2009; 50: 309-315.
34. Griffey RT, Sodickson A,. Cumulative radiation exposure and cancer risk estimates in emergency department patients undergoing repeat or multiple CT. AJR Am J Roentgenol 2009; 192: 887-892.
35. Tosun D, Schuff N, Mathis CA, et al. Spatial patterns of brain amyloid-β burden and atrophy rate associations in mild cognitive impairment. Brain 2011; 134 (pt 4): 1077-1088.
36. Tosun D, Schuff N, Truran-Sacrey D, et al. Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study. Neurobiol Aging 2010; 31: 1340-1354.
37. Chetelat G, Villemagne VL, Pike KE, et al. Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. Brain 2011; 134: 798-807.
38. Apostolova LG, Hwang KS, Andrawis JP, et al. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging 2010; 31: 1284-1303.
39. Hampel H, Burger K, Pruessner JC, et al. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol 2005; 62: 770-773.
40. Henneman WJP, Vrenken H, Barnes J, et al. Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. Neurology 2009; 73: 935-940.
41. de LaCoste M-C, White CL,. The role of cortical connectivity in Alzheimer's disease pathogenesis: a review and model system. Neurobiol Aging 1993; 14: 1-16.
42. Ashburner J, Hutton C, Frackowiak R, et al. Identifying global anatomical differences: deformation-based morphometry. Hum Brain Mapp 1998; 6: 348-357.
43. Stephan BCM, Hunter S, Harris D, et al. The neuropathological profile of mild cognitive impairment (MCI): a systematic review. Mol Psychiatry 2012; 17: 1056-1076.
44. Schneider JA, Aggarwal NT, Barnes L, et al. The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis 2009; 18: 691-701.
45. Madsen SK, Ho AJ, Hua X, et al. 3D maps localize caudate nucleus atrophy in 400 Alzheimer's disease, mild cognitive impairment, and healthy elderly subjects. Neurobiol Aging 2010; 31: 1312-1325.
46. Looi JC, Rajagopalan P, Walterfang M, et al. Differential putaminal morphology in Huntington's disease, frontotemporal dementia and Alzheimer's disease. Aust N Z J Psychiatry 2012; 46: 1145-1158.